Please ensure Javascript is enabled for purposes of website accessibility
Home > Products > Antibodies > Research Grade Biosimilars

Anti-HIV1 gp120/Glycoprotein 120 Reference Antibody (VRC01LS, RUO) (VK617066)

Anti-HIV1 gp120/Glycoprotein 120 Reference Antibody (VRC01LS, RUO)
Anti-HIV1 gp120/Glycoprotein 120 Reference Antibody (VRC01LS, RUO)
Anti-HIV1 gp120/Glycoprotein 120 Reference Antibody (VRC01LS, RUO)
Anti-HIV1 gp120/Glycoprotein 120 Reference Antibody (VRC01LS, RUO)
Price(USD):
Spec:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Number:
Get quote
  • Overview

  • Images

  • References

  • Datasheet

  • SDS

Overview
Catalog No.VK617066
Species reactivityHuman immunodeficiency virus 1 (HIV-1)
ApplicationsELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host speciesHuman
IsotypeIgG
Clone IDVRC01LS
Expression system Mammalian cells
Clonality Monoclonal
Target gp120/Glycoprotein 120
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G purified from cell culture supernatant.
Accession Q03805
Form Liquid
Storage buffer 0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Stability and Storage Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate NamesVRC01LS
Background

Envelope glycoprotein gp160 (gp120/Glycoprotein 120) is a ~96 kDa protein. Envelope glycoprotein gp160: Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41.

References 1. Happe M, et al. Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection. JCI Insight. 2025 Feb 24;10(4):e181496. [VK617066]
2. Gaudinski MR, et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med. 2018 Jan 24;15(1):e1002493. [VK617066]
Note For research use only. Not suitable for clinical or therapeutic use.
Images
  • Anti-HIV1 gp120/Glycoprotein 120 Reference Antibody (VRC01LS, RUO)

    Bioactivity

    Detects recombinant HIV1 gp120 (Catalog No: VK617011) in indirect ELISA.

  • Anti-HIV1 gp120/Glycoprotein 120 Reference Antibody (VRC01LS, RUO)

    Bioactivity

    Detects recombinant HIV1 gp120 (Catalog No: VK617021) in indirect ELISA.

References
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: support@abinScience.com

Distributor list